Announcing the BoSD Early Career Award
Springer Nature is sponsoring the Biology of Sex Differences (BoSD) Early Career Award for the best paper published in BoSD each year.
Nominations are now being accepted for two awards:
- 2024 Award for articles published in BoSD from January
- 2021 through August 2023 2025 Award for articles published in BoSD from September 2023 through August 2024
Two awards will be given at OSSD 2025
Winners will give talks at OSSD 2025 and receive a $1000 travel award.
- Nominee will be first author or senior author on a paper published in BoSD - co-first authors may be nominated and split the award/talk AND
- Graduate students at time of manuscript submission OR
- Post-docs at time of manuscript submission OR
- Investigators up to 6 years after training completion (post-doctoral/residency) at time of award (OSSD meeting)
Deadline September 2024 for nomination
Send a brief nomination letter, the manuscript & CV to Jill B. Becker, EIC jbbecker@med.umich.edu
This information may be included with submission for new manuscripts and manuscripts will be considered for the award after peer review.
Featured Article: Treating sex and gender differences as a continuous variable can improve precision cancer treatments
Treating sex and gender differences as a continuous variable can improve precision cancer treatments.
Authors: Wei Yang, Joshua B. Rubin
Published:15th April 2024
Some efforts to improve cancer therapy involve the idea of personalizing treatments to who a patient is and how their cancer operates. Personalizing treatment can involve straighforward features like a patient’s age, family cancer history, personal disease and surgical histories, as well as more complex features like analysis of their specific cancer’s mechanisms of growth and spread throughout the body. One glaring omission in common personalization schemes is the sex and gender of the patient. While patient sex and gender is known to substantially affect cancer rates and response to treatment, we do not yet use this information in treatment planning. There are multiple reasons for this but among them is that we tend to think about sex and gender as an either/or categorization. You are either a male/man or a female/woman. This is not accurate as there are many variables that contribute to who an individual is as a male/man or female/woman. This variability is a challenge to incorporating these features into personalized treatment planning. Here, we have developed a method to address this challenge. It is our great hope that this will enable the use of this critically important element of personalization in cancer treatment planning and improve survival rates for all patients.
New special collections now publishing
Read more about our newly launched Collection on the topic of Sex/Gender Differences in Cancer.
